Product Highlight-Shingrix

Shingrix (recombinant zoster vaccine, adjuvanted) is indicated for the prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN) in adults 50 years of age or older, and in adults 18 years of age or older who are at increased risk of HZ.¹

• Efficacy:¹
- Shingrix offers 97% efficacy for adults ≥50 years of age.
- Shingrix offers 91% efficacy for adults ≥70 years of age.
• Protection That Lasts:²
- Shingrix demonstrated clinical benefit for up to 10 years, with 89% efficacy against shingles.
• Established safety profile:²
- The safety profile remained clinically acceptable up to 10 years post-vaccination.

Shingrix is contraindicated in anyone with hypersensitivity to the active substances or to any of the excipients.¹

References:
1. Shingrix Prescribing Information [Shingrix Prescribing Information v01 Malaysia].
2. Strezova A, et al. Long-term protection against Herpes Zoster by the adjuvanted Recombinant Zoster Vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination. Open Forum Infectious Diseases. 2022.

This educational program is sponsored by GSK.

Before prescribing, scan the QR code to refer to the full prescribing information.
For any access issues, please contact GSK Malaysia at medinfo.my@gsk.com.

For Malaysia Healthcare Professionals Only
Adverse events should be reported to drugsafetyinfo.my@gsk.com
PM-MY-SGX-WCNT-250001 (01/25)